ROR1 protein, human – Talk Bio

Actionable Insights Powered by AI

Radiance Biopharma Secures $1.2 Billion Deal for Novel ROR1-Targeted Antibody-Drug Conjugate from CSPC

2 months ago talkbio0Tagged Antibody-Drug Conjugates, biopharmaceutical partnership, Dosage Forms, GZMH gene, Neoplasms, Radiance Biopharma, ROR1 protein, human

Radiance Biopharma, CSPC Pharmaceutical, ROR1, antibody-drug conjugate (ADC), oncology, licensing deal, biopharmaceutical partnership

Merck’s Investigational ADC Zilovertamab Vedotin Enters Phase 3 with 100% Complete Response Rate in DLBCL Patients

5 months ago talkbio0Tagged Antibody-Drug Conjugates, Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Phase 2 trial, Phase 3 trial, Programs - Publication Format, ROR1 protein, human, vedotin, Zilovertamab

Zilovertamab Vedotin, Antibody-Drug Conjugate (ADC), Diffuse Large B-Cell Lymphoma (DLBCL), Phase 2 Trial, Phase 3 Trial, ROR1, Merck, waveLINE Program